NCT06816160|RecruitingDMC
TRU-Cut Biopsy in Tumor cHaracterisation
TRUTH
Tru-cut Biopsy in Tumor Characterisation
Loading search results
TRUTH
Tru-cut Biopsy in Tumor Characterisation
Sponsor study identifier
observational
250
1 country
1
Study Start
February 1, 2024
Actual (reported)Primary Completion
January 31, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Tru-cut biopsy (TCB) is a minimally invasive method to get an adequate sample from the lesion in order to tailor the appropriate management avoiding unnecessary surgery. The aim of our trial is to evaluate the adequacy, accuracy and safety of the method related to the final histology as reference standard.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1, 2024
Actual (reported)March 2, 2024
Actual (reported)February 10, 2025
Actual (reported)January 31, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The adequacy of samples obtained by TCB for histopathological examination (in %)
1\. The adequacy means the ability to determine the type of tumor (in %)
First data 31st of June 2025, definitive data 31st of January 2026
The adequacy of samples obtained by TCB for next-generation sequencing examination (in %)
First data 31st of June 2025, definitive data 31st of January 2026
The adequacy of samples obtained by TCB for immunohistochemistry examination (in %)
First data 31st of June 2025, definitive data 31st of January 2026
The adequacy of samples obtained by TCB for immunologic examination (in %)
First data 31st of June 2025, definitive data 31st of January 2026
1. To evaluate which factors affect the primary and secondary endpoints 2. To evaluate the overall safety of TCB (in %) 3. To evaluate the overall accuracy of TCB for complex classification of pelvic and abdominal tumors (in %)
First data 31st of June 2025, definitive data 31st of January 2026
Overall safety of TCB (in %)
First data 31st of June 2025, definitive data 31st of January 2026
Overall accuracy of TCB for complex classification of pelvic and abdominal tumors (in %)
First data 31st of June 2025, definitive data 31st of January 2026
needle biopsy from the tumor
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Women with abdominopelvic tumor
Department of Gynecology, Obstetrics and Neonatology of First Faculty of Medicine and General University Hospital in Prague
Prague, 12800, Czechia
Biopsy from tumor
David Cibula, prof.
Department of Gynecology, Obstetrics and Neonatology
First Submitted
March 2, 2024
First Posted
February 10, 2025
Study Start
February 1, 2024
Actual (reported)Primary Completion
January 31, 2026
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 10, 2025
Record last verified: 2025-02
Registration of subjects into the database using the REDCap (Research Electronic Data Capture, www.projectredcap.org) electronic data capture tool.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: